Compare HUT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | PCVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2023 | 2020 |
| Metric | HUT | PCVX |
|---|---|---|
| Price | $47.81 | $58.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | $56.93 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $235,118,000.00 | N/A |
| Revenue This Year | $161.69 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $10.11 | $28.09 |
| 52 Week High | $66.07 | $65.00 |
| Indicator | HUT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 56.87 |
| Support Level | $45.55 | $42.30 |
| Resistance Level | $55.90 | $58.95 |
| Average True Range (ATR) | 3.61 | 2.13 |
| MACD | -0.26 | 0.28 |
| Stochastic Oscillator | 40.85 | 81.15 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.